Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer.

Ying FuQing LiuXiaohan WangLiangchao SunXiao Han Xue Meng

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)

In ALK+ NSCLC, longer EML4-ALK variants correlate with improved prognosis and enhanced response to second-generation ALKi, while TP53 co-mutations indicate a negative prognosis.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
copy number
tyrosine kinase
gene expression